# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence S...
This ruling paves the way for Exact Sciences to seek relief for Geneoscopy's future infringement and false advertising. ...
BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $85 to $80.
Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $90...
Citigroup analyst Patrick Donnelly maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $100 t...
Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising u...